Société RXi Pharmaceuticals Corp OTC Bulletin Board
Actions
US74979C1053
Recherche biotechnologique et médicale
Cours en clôture
Autres places de cotation
|
||
- USD | - |
Métier
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 10/11/22 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Director/Board Member | 73 | 02/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/04/13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 07/06/17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 01/10/19 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 510 189 | 506 959 ( 99,37 %) | 0 | 99,37 % |
Coordonnées société
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+25,83% | 46,56 Md | |
+45,38% | 41,67 Md | |
+0,69% | 41,16 Md | |
+30,52% | 32,4 Md | |
+22,30% | 28,18 Md | |
-6,35% | 28,1 Md | |
+49,25% | 14,52 Md | |
+49,18% | 13,74 Md | |
+3,45% | 12,17 Md |
- Bourse
- Actions
- Action PHIO
- Action
- Société RXi Pharmaceuticals Corp